Omacetaxine as an anticancer therapeutic: What is old is new again

Current Pharmaceutical Design

Volumn 17, Issue 1, 2011, Pages 59-64

  Wetzler, Meir ^a   Segal, David ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

cancer stem cells; chronic myeloid leukemia; leukemia initiating cells; Omacetacine; protein translation inhibition

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABELSON KINASE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYCLIN D1; DASATINIB; DOXORUBICIN; EVEROLIMUS; IMATINIB; MYC PROTEIN; NILOTINIB; OMACETAXINE; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TEMSIROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; GENE EXPRESSION REGULATION, LEUKEMIC; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, GENETIC; NEOPLASTIC STEM CELLS; PROTEIN SYNTHESIS INHIBITORS;

EID: 79953743709     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795049778     Document Type: Review

References (62)

1. Fresno M, Jimenez A, Vazquez D. Inhibition of translation in eu- karyotic systems by harringtonine. Eur J Biochem 1977; 72(2): 323-330.
2. Huang MT. Harringtonine, an inhibitor of initiation of protein bio- synthesis. Mol Pharmacol 1975; 11(5): 511-519.
3. Gurel G, Blaha G, Moore PB, Steitz TA. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribo- some. J Mol Biol 2009; 389(1): 146-156.
4. Hershey JWB, Miyamato S. Translational control and cancer. In: Sonenberg N, Hershey JWB, Mathews MB, editors. Translational Control of Gene Expression. New York: Cold Spring Harbor Labo- ratory Press; 2000. pp. 637-654.
5. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev 2010; 10(4): 254-266.
6. Bordeleau ME, Robert F, Gerard B, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008; 118(7): 2651-2660.
7. Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J. Altering chemosensitivity by modulating translation elongation. PLoS One 2009; 4(5): e5428.
8. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addic- tion in chronic myelogenous leukemia. Cancer Res 2006; 66(22): 10959-10966.
9. Kuroda J, Kamitsuji Y, Kimura S, et al. Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma- promoting molecules, Mcl-1, XIAP, and beta-catenin. Int J Hematol 2008; 87(5): 507-515.
10. Tang R, Faussat AM, Majdak P, et al. Semisynthetic homoharring- tonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006; 5(3): 723-731.
11. Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res 2008; 68(13): 5326-5334.
12. Lin CJ, Malina A, Pelletier J. c-Myc and eIF4F constitute a feed- forward loop that regulates cell growth: implications for anticancer therapy. Cancer Res 2009; 69(19): 7491-7494.
13. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mu- tations in patients with CML treated with imatinib is virtually al- ways accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor progno- sis. Blood 2003; 102(1): 276-283.
14. Parmar S, Smith J, Sassano A, et al. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 2005; 106(7): 2436-2443.
15. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E- BP1 in chronic myelogenous leukemia cells via the mammalian tar- get of rapamycin. Cancer Res 2003; 63(18): 5716-5722.
16. Zhang M, Fu W, Prabhu S, et al. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol 2008; 28(20): 6496-6509.
17. Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL- induced chronic myeloid leukemia and acute lymphoblastic leuke- mia in mice. Leukemia 2009; 23(8): 1446-1454.
18. Kuroda J, Kimura S, Andreeff M, et al. ABT-737 is a useful com- ponent of combinatory chemotherapies for chronic myeloid leu- kaemias with diverse drug-resistance mechanisms. Br J Haematol 2008; 140(2): 181-190.
19. Xiang Z, Luo H, Payton JE, et al. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Invest 2010; 120(6): 2109-2118.
20. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 1989; 63(5): 813-817.
21. Jin J, Jiang DZ, Mai WY, et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 2006; 20(8): 1361-1367.
22. Zhang WG, Wang FX, Chen YX, et al. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte col- ony-stimulating factor priming in patients with relapsed or refrac- tory acute myeloid leukemia. Am J Hematol 2008; 83(3): 185-188.
23. Wang J, Lu S, Yang J, et al. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China. J Hematol Oncol 2009; 2: 32.
24. Wu L, Li X, Su J, et al. Effect of low-dose cytarabine, homohar- ringtonine and granulocyte colony-stimulating factor priming regi- men on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Leuk Lymphoma 2009; 50(9): 1461-1467.
25. Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homo- harringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 2011; 117(1): 156-164.
26. Jin Y, Lu Z, Cao K, et al. The antitumor activity of homoharring- tonine against human mast cells harboring the KIT D816V muta- tion. Mol Cancer Ther 2010; 9(1): 211-223.
27. Meng HT, Li L, Liu H, Wang Y, Li GC, Qian WB. Homoharring- tonine acts synergistically with SG235-TRAIL, a conditionally rep- licating adenovirus, in human leukemia cell lines. Acta Pharmacol Sin 2009; 30(11): 1529-1536.
28. Mawji IA, Simpson CD, Gronda M, et al. A chemical screen identi- fies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. Cancer Res 2007; 67(17): 8307-8315.
29. Jorgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 2007; 35(Pt 5): 1347-1351.
30. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinua- tion in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109(1): 58-60.
31. Allan EK, Jorgensen HG, Michaels S, Holyoake TL, editors. Oma- cetaxine cytotoxic activity in chronic myeloid leukemia stem cells. Haematologica 2009; 1052 (abs).
32. Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12(6): 528-541.
33. Hu Y, Chen Y, Douglas L, Li S. beta-Catenin is essential for sur- vival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009; 23(1): 109-116.
34. Broad Institute. [cited 2010]; Available from: http: //chembank. broadinstitute.org/chemistry/viewMolecule.htm?cbid=3176388.
35. Klag T, Hartel N, Schenk T, Craig AR, Hochhaus A, Rosee PL. Downregulation of the common cytokine receptor subunit beta c by omacetaxine in CML: a potential molecular mechanism to over- come cytokine-mediated resistance against BCR-ABL-inhibitors. Blood 2009; 114(22): 3256 (Abs).
36. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009; 15(9): 1010-1012.
37. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138(4): 645-659.
38. Kantarjian HM, Cortes J, La Rosee P, Hochhaus A. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer 2010; 116(6): 1419-1430.
39. O'Dwyer PJ, King SA, Hoth DF, Suffness M, Leyland-Jones B. Homoharringtonine--perspectives on an active new natural product. J Clin Oncol 1986; 4(10): 1563-1568.
40. O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86(9): 3322-3326.
41. O'Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharring- tonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 2002; 94(7): 2024-2032.
42. Quintas-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 2009; 115(23): 5382-5393.
43. Cortes-Franco J, Khoury HJ, Nicolini FE, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr- Abl T315I mutation-results of an ongoing multicen- ter phase 2/3 study. Blood 2009; 114(22): 644 (Abs).
44. Cortes-Franco J, Raghunadharao D, Parikh P, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multicenter phase 2/3 Study. Blood 2009; 114(22): 861 (Abs).
45. Ni D, Ho DH, Vijjeswarapu M, Felix E, Rhea PR, Newman RA. Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia. J Exp Ther Oncol 2003; 3(1): 47-52.
46. Levy V, Zohar S, Bardin C, et al. A phase I dose-finding and phar- macokinetic study of subcutaneous semisynthetic homoharring- tonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer 2006; 95(3): 253-259.
47. Brown D, Michaels S. Design and evaluation of oral delivery dos- age forms of homoharringtonine. AACR Annual Meeting Abstracts 2007: Abstract 4730.
48. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV. Drug responses of imatinib mesylate-resistant cells: syn- ergism of imatinib with other chemotherapeutic drugs. Leukemia 2002; 16(12): 2349-2357.
49. Marin D, Kaeda JS, Andreasson C, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia pa- tients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005; 103(9): 1850-1855.
50. Bruey JM, Kantarjian HM, Ma W, et al. A Common but Over- looked Mechanism of BCR-ABL1 Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. Blood 2009; 114(22): 2179.
51. Ayoubi M, Kantarjian HM, Wierda W, et al. A phase 2 study of the combination of omacetaxine and imatinib in the treatment of pa- tients with chronic myeloid leukemia (CML) in advanced stages or after failure to imatinib. Blood 2009; 114(22): 2193 (Abs).
52. Nicolini FE, Chomel JC, Roy L, et al. The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myeloge- nous leukemia patients on omacetaxine allows tyrosine kinase in- hibitor rechallenge. Clin Lymphoma Myeloma Leuk 2010; 10(5): 394-399.
53. Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate re- sponse in patients receiving nilotinib or dasatinib as second or sub- sequent line therapy for chronic myeloid leukemia. Blood 2008; 112(3): 516-518.
54. Garg RJ, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long- term follow-up. Blood 2009; 114(20): 4361-4368.
55. Okano T, Ohnuma T, Holland JF, Koeffler HP, Jui H. Effects of harringtonine in combination with acivicin, adriamycin, L- asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG- 1. Invest New Drugs 1983; 1(2): 145-150.
56. Warrell RP, Jr., Coonley CJ, Gee TS. Homoharringtonine: an effec- tive new drug for remission induction in refractory nonlymphoblas- tic leukemia. J Clin Oncol 1985; 3(5): 617-621.
57. Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 1992; 6(11): 1185-1188.
58. Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine in combi- nation with cytarabine for patients with acute myelogenous leuke- mia. Leukemia 1992; 6(11): 1189-1191.
59. Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA. Homohar- ringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 1996; 10(1): 40-42.
60. Borthakur G, Kantarjian H, Estey E, Verstovsek S, Garcia-Manero G, Cortes J. Study of intra-venous homoharringtonine (HHT) in the treatment of myelodysplastic syndrome (MDS). Blood 2005; 106(11): 4903 (Abs).
61. Xu WL, Jin J, Qian WB. Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syn- dromes. Chin Med J (Engl) 2010; 123(1): 108-110.
62. Lu LH, Lin SP, Liang YY, Song TY, Li LY. Harringtonine in treatment of polycythemia vera. Chin Med J (Engl) 1983; 96(7):533-535.